JAZZ - ImmunoGen: Update On A Turnaround Story

• After ImmunoGen shares were decimated, the company learned from its mistakes. And, they're now embarking on a path toward a spectacular turnaround.
• The lead medicine, Mirve, is progressing in two Phase 3 trials with a data release as early as next year.
• Meanwhile, other pipeline molecules are advancing at a rapid clip. Nonetheless, the stock is still trading at a deep bargain to its true worth.

For further details see: